The ABPI has today launched a members’ guide to the Concordat on Openness on Animal Research in the UK aimed at supporting companies signed up to the Concordat to meet the pledge to be more open about the ways in which they use animals in scientific research.
More than 80 organisations involved with life sciences, including universities, learned societies and pharmaceutical companies, have signed the
Concordat on Openness on Animal Research in the UK and are committed to being more transparent about the role animals have in scientific research.
This includes the ABPI and member companies who have signed up to the Concordat with the aim of providing accurate, up-to-date information about the role animal research plays in the discovery and development of medicines and treatments, how it is regulated, the importance of animal welfare and the drive to replace, refine and reduce the way that animals are used in research. The
guide has been developed to support companies by providing advice on practical steps they can take to create a culture of openness.
Dr Virginia Acha, Executive Director Research, Medical and Innovation said: “Animal research has played an important role in the development of nearly all medicines we take for granted today and whilst great advances have been made in alternative techniques, the complexity of the human body means it cannot yet be fully modelled by these methods, and therefore animals continue to play a critical role in the discovery and development of medicines.
“However, no one wants to use animals in research when they don’t have to, and the bio-pharmaceutical industry in the UK is committed to reducing and ultimately replacing the use of animals in scientific research. Whilst animal research remains necessary companies take the welfare of animals in their care incredibly seriously and are increasingly committed to being open about the work undertaken with animals. This guide is another step in assisting companies, particularly ABPI members, to maximise their openness and meet the commitments of the Concordat.”
Today’s launch coincides with the
EU Commission’s response to the Stop Vivisection European Citizens’ Initiative and the decision not to repeal European Directive 2010/63/EU on the protection of animals for scientific research purposes. The Directive is essential in facilitating the development of life-saving and life-enhancing medicines whilst encouraging the highest standards of animal welfare and requiring researchers to support the 3Rs to replace, refine and reduce the way animals are used in research and the ABPI welcomes the Commission’s decision.
Dr Acha added: “This Directive is leading to improved animal welfare standards across Europe and commits researchers to make every effort to seek alternatives and we welcome the Commission’s decision on the petition to repeal. It is the right decision for the animals used in scientific research and the patients who benefit from the resulting medicines and treatments.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com